BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20890046)

  • 1. Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.
    Stromnes IM; Blattman JN; Tan X; Jeevanjee S; Gu H; Greenberg PD
    J Clin Invest; 2010 Oct; 120(10):3722-34. PubMed ID: 20890046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity.
    Shamim M; Nanjappa SG; Singh A; Plisch EH; LeBlanc SE; Walent J; Svaren J; Seroogy C; Suresh M
    J Immunol; 2007 Dec; 179(11):7233-43. PubMed ID: 18025165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
    Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
    J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.
    Qiao G; Li Z; Molinero L; Alegre ML; Ying H; Sun Z; Penninger JM; Zhang J
    Mol Cell Biol; 2008 Apr; 28(7):2470-80. PubMed ID: 18227156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene.
    Yang T; Martin ML; Nielsen JS; Milne K; Wall EM; Lin W; Watson PH; Nelson BH
    Cancer Immunol Immunother; 2009 Nov; 58(11):1865-75. PubMed ID: 19350239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.
    Krawczyk CM; Jones RG; Atfield A; Bachmaier K; Arya S; Odermatt B; Ohashi PS; Penninger JM
    J Immunol; 2005 Feb; 174(3):1472-8. PubMed ID: 15661906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of the major compatibility complex-dependent development of CD4+ and CD8+ T cells by the Cbl family proteins.
    Huang F; Kitaura Y; Jang I; Naramura M; Kole HH; Liu L; Qin H; Schlissel MS; Gu H
    Immunity; 2006 Oct; 25(4):571-81. PubMed ID: 17045823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
    Hinterleitner R; Gruber T; Pfeifhofer-Obermair C; Lutz-Nicoladoni C; Tzankov A; Schuster M; Penninger JM; Loibner H; Lametschwandtner G; Wolf D; Baier G
    PLoS One; 2012; 7(9):e44295. PubMed ID: 22962608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cbl-b regulates the CD28 dependence of T-cell activation.
    Chiang YJ; Kole HK; Brown K; Naramura M; Fukuhara S; Hu RJ; Jang IK; Gutkind JS; Shevach E; Gu H
    Nature; 2000 Jan; 403(6766):216-20. PubMed ID: 10646609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
    Loeser S; Loser K; Bijker MS; Rangachari M; van der Burg SH; Wada T; Beissert S; Melief CJ; Penninger JM
    J Exp Med; 2007 Apr; 204(4):879-91. PubMed ID: 17403934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation.
    Li D; Gál I; Vermes C; Alegre ML; Chong AS; Chen L; Shao Q; Adarichev V; Xu X; Koreny T; Mikecz K; Finnegan A; Glant TT; Zhang J
    J Immunol; 2004 Dec; 173(12):7135-9. PubMed ID: 15585834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis, but increases plaque T cell infiltration and systemic T cell activation.
    Vos WG; van Os BW; den Toom M; Beckers L; van Roomen CPAA; van Tiel CM; Mohapatra BC; Band H; Nitz K; Weber C; Atzler D; de Winther MPJ; Bosmans LA; Lutgens E; Seijkens TTP
    Front Immunol; 2024; 15():1297893. PubMed ID: 38504977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
    Crossland KD; Lee VK; Chen W; Riddell SR; Greenberg PD; Cheever MA
    J Immunol; 1991 Jun; 146(12):4414-20. PubMed ID: 1674958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.
    Bachmaier K; Krawczyk C; Kozieradzki I; Kong YY; Sasaki T; Oliveira-dos-Santos A; Mariathasan S; Bouchard D; Wakeham A; Itie A; Le J; Ohashi PS; Sarosi I; Nishina H; Lipkowitz S; Penninger JM
    Nature; 2000 Jan; 403(6766):211-6. PubMed ID: 10646608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
    J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.